Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/11/2025 | $12.00 | Buy | H.C. Wainwright |
| 12/30/2024 | $20.00 | Buy | H.C. Wainwright |
| 8/13/2024 | $21.00 | Buy | Jefferies |
| 8/13/2024 | $23.00 | Overweight | Cantor Fitzgerald |
| 8/13/2024 | Buy | TD Cowen | |
| 8/13/2024 | $18.00 | Outperform | Wedbush |
| 8/13/2024 | $23.00 | Buy | Needham |
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell depleting category to receive this designation with the potential to become the first in the category to advance to a pivotal trial in RA, pending FDA feedback expected in 1H 2026 Continued execution and enrollment progress with more than 20 patients treated with AlloNK + monoclonal antibody (mAb) therapy across company-sponsored and investigator-initiated trials in autoimmune diseases Upcoming translational data release expected to show uniform, consistent, deep B-cell d
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 on Wednesday, September 3, 2025, at 9:45 a.m. EDT. Members of the Artiva management team will also be available to participate in investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through t
First patient treated in company-sponsored global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies, and systemic sclerosis Continued execution and enrollment progress with over a dozen patients treated with AlloNK + mAb across over a dozen sites in company-sponsored and investigator-initiated clinical trials in autoimmune diseases Initial safety, translational data, and lead indication selection for AlloNK in autoimmune diseases to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Cash runway into Q2 2027, with cash, cash equivalents, and i
H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00
Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
EFFECT - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
S-3 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
S-8 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026 Longer-term clinical data from Phase 1/2 trial exploring AlloNK + rituximab in B-NHL in heavily pretreated CAR-T naïve patients to be presented at ASGCT, demonstrating complete response rates and
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Subhashis Banerjee, M.D., as Chief Medical Officer. Dr. Banerjee is a trained rheumatologist and immunologist who brings over two decades of clinical development experience in autoimmune diseases, most recently as Disease Area Head for Rheumatology and Dermatology Global Development at Bristol Myers Squibb (BMS), and Senior Vice President (SVP), Clinical Development at VYNE Therapeutics, Inc.
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Dan Baker, M.D., as an independent member of its Board of Directors. Dr. Baker brings over two decades of drug development experience in the pharmaceutical industry. He is currently the interim Chief Development Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at Johnson & Johnson (Janssen/Centocor) (J & J) most recently as the Vice President of Immunology R&D. "Dan is a ph
SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)